摘要
探讨渴络欣胶囊对db/db小鼠早期糖尿病视网膜病(diabetic retinopathy,DR)的改善作用。采用目前国际公认的8周龄雄性(45~55 g)db/db自发性糖尿病小鼠动物模型,每周称取体质量和空腹血糖1次,根据体质量灌胃给药。渴络欣低、中、高剂量组灌胃剂量分别为780,1 560,3 120 mg·kg-1·d-1;羟苯磺酸钙组灌胃剂量为195 mg·kg-1·d-1;对照组和模型组均灌胃相等体积生理盐水;各组连续给药20周。灌胃结束后,进行视网膜光学相干断层扫描,眼底荧光血管造影和视网膜电图。小鼠摘取眼球,分离视网膜,制作石蜡切片,HE染色;免疫组化检测视网膜胶质纤维酸性蛋白表达。渴络欣胶囊对db/db小鼠体质量和空腹血糖并无显著调节作用。相干断层实验结果表明,渴络欣胶囊能够显著改善小鼠视网膜神经节层和内丛状层的厚度;眼底荧光造影结果表明,渴络欣胶囊能够一定程度改善早期糖尿病视网膜病微血管数量;ERG实验表明渴络欣胶囊能够改善DR早期视网膜功能。视网膜组织病理切片染色证实渴络欣胶囊能够一定程度改善各层细胞排列不规则、水肿,免疫组化实验结果显示各组视网膜组织并未出现明显的胶质化。该研究结果表明,渴络欣胶囊能够显著降低db/db糖尿病小鼠视网膜神经节层和内丛状层的厚度;改善DR早期视网膜功能;改善视网膜各层水肿、排列紊乱等。提示渴络欣胶囊能够防治早期糖尿病视网膜病,这为临床上渴络欣治疗糖尿病视网膜病提供了实验依据。
The aim of this paper was to investigate the preventive effects of Keluoxin Capsules(KLX)on diabetic retinopathy in db/db mice.One hundred male db/db diabetic mice(45-55 g,8 weeks)were randomly divided into 5 groups(model,KLX low dose,KLX middle dose,KLX high dose,Dobesilate)and 20 male C57 BL/KsJdb+/+were taken as control group.Body weight and fasting blood-glucose were detected every week.Mice were administrated with saline(control and model group),KLX(780,1 560,3 120 mg·kg-1·d-1,ig),Dobesilate(195 mg·kg-1·d-1,ig)for 20 weeks,respectively.At the end of the administration,optical coherence tomography,fundus fluorescein angiography and electroretinogram of the retina were measured.The eyeball was extirpated and retina was isolated to make paraffin section,followed by HE staining and glial fibrillary acidic protein(GFAP)immunohistochemistry.The results indicated that KLX has no obvious effect on body weight and fasting blood level in db/db mice.However,KLX could significantly regulate the thickness of retinal ganglion layer and inner plexiform layer.KLX was able to remarkably reduce the quantity of diabetic microvessel.Meanwhile,KLX could notably improve retinal function.Moreover,KLX could observably modulate the cell arrangement and edema in each layer.There was no markable difference in retina according to the immunochemistry assay.In the present study,KLX exert marked preventive effects on diabetic retinopathy in db/db mice,which provided an experimental evidence for clinical use.
作者
罗云
卢珊
刘立涛
许可
赵曼茜
叶亮
吴荃
滕传震
柯潇
孙桂波
孙晓波
LUO Yun;LU Shan;LIU Li-tao;XU Ke;ZHAO Man-qian;YE Liang;WU Quan;TENG Chuan-zhen;KE Xiao;SUN Gui-bo;SUN Xiao-bo(Institute of Medicinal Plant Development,Peking Union Medical College and Chinese Academy of Medical Sciences,Beijing100193,China;Chengdu Kanghong Pharmaceuticals Group,Chengdu610036,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2019年第11期2324-2330,共7页
China Journal of Chinese Materia Medica
基金
国家自然科学基金项目(81703745)
